Clinical Trial Update: A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating a combination of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine in patients with advanced melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• HyperAcute Melanoma Vaccine
• Pegylated Interferon Alpha-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: Ochsner Health System | Conditions: Melanoma | Phase 2 | Status: UNKNOWN